[{"orgOrder":0,"company":"Dimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DMX-200","moa":"CCR2","graph1":"Nephrology","graph2":"Phase III","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dimerix \/ Undisclosed"},{"orgOrder":0,"company":"Dimerix","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Nephrology","graph2":"Phase III","graph3":"Dimerix","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.58999999999999997,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Dimerix \/ Amicus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Dimerix \/ Amicus Therapeutics"},{"orgOrder":0,"company":"Dimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Nephrology","graph2":"Phase III","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Dimerix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dimerix \/ Undisclosed"},{"orgOrder":0,"company":"Dimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Dimerix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dimerix \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Dimerix \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Dimerix

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Under the licensing agreement, Amicus holds the commercialization rights to DMX-200 (repagermanium), an advanced-stage treatment for Focal Segmental Glomerulosclerosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $30.0 million

                          April 30, 2025

                          Lead Product(s) : Propagermanium

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Amicus Therapeutics

                          Deal Size : $590.0 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : DMX-200 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glomerulosclerosis, Focal Segmental.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 10, 2022

                          Lead Product(s) : DMX-200

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Primary and secondary endpoints met in the Phase 2a study of DMX-200 in FSGS patients, 86% of patients demonstrated a reduction of proteinuria with DMX-200 versus placebo.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 29, 2020

                          Lead Product(s) : Propagermanium

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : DMX-200 has been selected for inclusion in the protocol as a new treatment arm in the global the REMAP-CAP program aimed at treating patients with Acute Respiratory Distress Syndrome (ARDS) as a result of COVID-19.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 04, 2020

                          Lead Product(s) : Propagermanium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank